Logo image of IMGN

ImmunoGen Inc (IMGN) Stock Fundamental Analysis

USA - NASDAQ:IMGN - US45253H1014 - Common Stock

31.23 USD
0 (0%)
Last: 2/9/2024, 8:00:02 PM
31.24 USD
+0.01 (+0.03%)
After Hours: 2/9/2024, 8:00:02 PM
Fundamental Rating

3

Overall IMGN gets a fundamental rating of 3 out of 10. We evaluated IMGN against 534 industry peers in the Biotechnology industry. While IMGN seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, IMGN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

IMGN had negative earnings in the past year.
IMGN had a negative operating cash flow in the past year.
In the past 5 years IMGN always reported negative net income.
IMGN had a negative operating cash flow in each of the past 5 years.
IMGN Yearly Net Income VS EBIT VS OCF VS FCFIMGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M -200M

1.2 Ratios

IMGN has a Return On Assets of -8.94%. This is amongst the best in the industry. IMGN outperforms 89.06% of its industry peers.
The Return On Equity of IMGN (-13.09%) is better than 89.06% of its industry peers.
Industry RankSector Rank
ROA -8.94%
ROE -13.09%
ROIC N/A
ROA(3y)-34.29%
ROA(5y)-40.85%
ROE(3y)-78.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMGN Yearly ROA, ROE, ROICIMGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 -500 -1K -1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 98.61%, IMGN belongs to the top of the industry, outperforming 98.32% of the companies in the same industry.
IMGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMGN Yearly Profit, Operating, Gross MarginsIMGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

IMGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IMGN has been increased compared to 1 year ago.
Compared to 1 year ago, IMGN has a worse debt to assets ratio.
IMGN Yearly Shares OutstandingIMGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M
IMGN Yearly Total Debt VS Total AssetsIMGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

IMGN has an Altman-Z score of 18.14. This indicates that IMGN is financially healthy and has little risk of bankruptcy at the moment.
IMGN has a Altman-Z score of 18.14. This is amongst the best in the industry. IMGN outperforms 90.91% of its industry peers.
A Debt/Equity ratio of 0.16 indicates that IMGN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.16, IMGN is doing worse than 68.18% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 18.14
ROIC/WACCN/A
WACC11.02%
IMGN Yearly LT Debt VS Equity VS FCFIMGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M -200M 300M

2.3 Liquidity

IMGN has a Current Ratio of 5.69. This indicates that IMGN is financially healthy and has no problem in meeting its short term obligations.
IMGN has a Current ratio of 5.69. This is comparable to the rest of the industry: IMGN outperforms 56.57% of its industry peers.
A Quick Ratio of 5.65 indicates that IMGN has no problem at all paying its short term obligations.
IMGN has a Quick ratio (5.65) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.69
Quick Ratio 5.65
IMGN Yearly Current Assets VS Current LiabilitesIMGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.20% over the past year.
The Revenue has grown by 200.63% in the past year. This is a very strong growth!
The Revenue has been decreasing by -1.17% on average over the past years.
EPS 1Y (TTM)62.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%132.26%
Revenue 1Y (TTM)200.63%
Revenue growth 3Y9.75%
Revenue growth 5Y-1.17%
Sales Q2Q%636.36%

3.2 Future

IMGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.99% yearly.
IMGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 69.78% yearly.
EPS Next Y108.78%
EPS Next 2Y56.06%
EPS Next 3Y44.14%
EPS Next 5Y32.99%
Revenue Next Year344.16%
Revenue Next 2Y154.65%
Revenue Next 3Y109.41%
Revenue Next 5Y69.78%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IMGN Yearly Revenue VS EstimatesIMGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B
IMGN Yearly EPS VS EstimatesIMGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMGN. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 81.49, the valuation of IMGN can be described as expensive.
93.94% of the companies in the same industry are more expensive than IMGN, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.92. IMGN is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 81.49
IMGN Price Earnings VS Forward Price EarningsIMGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMGN Per share dataIMGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

IMGN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as IMGN's earnings are expected to grow with 44.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.06%
EPS Next 3Y44.14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ImmunoGen Inc

NASDAQ:IMGN (2/9/2024, 8:00:02 PM)

After market: 31.24 +0.01 (+0.03%)

31.23

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-09 2024-02-09/amc
Earnings (Next)04-26 2024-04-26/amc
Inst Owners0.16%
Inst Owner Change0%
Ins Owners0.43%
Ins Owner Change0%
Market Cap8.72B
Revenue(TTM)287.70M
Net Income(TTM)-73500000
Analysts70.53
Price Target31.69 (1.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)102.82%
Min EPS beat(2)85.91%
Max EPS beat(2)119.72%
EPS beat(4)4
Avg EPS beat(4)66.67%
Min EPS beat(4)23.99%
Max EPS beat(4)119.72%
EPS beat(8)6
Avg EPS beat(8)47.51%
EPS beat(12)10
Avg EPS beat(12)59.04%
EPS beat(16)13
Avg EPS beat(16)56.88%
Revenue beat(2)2
Avg Revenue beat(2)36.59%
Min Revenue beat(2)4.48%
Max Revenue beat(2)68.71%
Revenue beat(4)4
Avg Revenue beat(4)86.57%
Min Revenue beat(4)4.48%
Max Revenue beat(4)138.97%
Revenue beat(8)7
Avg Revenue beat(8)54.29%
Revenue beat(12)8
Avg Revenue beat(12)38.51%
Revenue beat(16)11
Avg Revenue beat(16)32.28%
PT rev (1m)0.02%
PT rev (3m)34.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.27%
EPS NY rev (1m)6.14%
EPS NY rev (3m)223.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.12%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)7.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 81.49
P/S 30.32
P/FCF N/A
P/OCF N/A
P/B 15.53
P/tB 15.53
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)0.38
Fwd EY1.23%
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS1.03
BVpS2.01
TBVpS2.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.94%
ROE -13.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.61%
FCFM N/A
ROA(3y)-34.29%
ROA(5y)-40.85%
ROE(3y)-78.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 109.3%
Cap/Sales 0.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.69
Quick Ratio 5.65
Altman-Z 18.14
F-Score4
WACC11.02%
ROIC/WACCN/A
Cap/Depr(3y)63.67%
Cap/Depr(5y)66.52%
Cap/Sales(3y)1.33%
Cap/Sales(5y)3.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%132.26%
EPS Next Y108.78%
EPS Next 2Y56.06%
EPS Next 3Y44.14%
EPS Next 5Y32.99%
Revenue 1Y (TTM)200.63%
Revenue growth 3Y9.75%
Revenue growth 5Y-1.17%
Sales Q2Q%636.36%
Revenue Next Year344.16%
Revenue Next 2Y154.65%
Revenue Next 3Y109.41%
Revenue Next 5Y69.78%
EBIT growth 1Y59.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.66%
EBIT Next 3Y43.02%
EBIT Next 5Y35.85%
FCF growth 1Y-71.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.08%
OCF growth 3YN/A
OCF growth 5YN/A

ImmunoGen Inc / IMGN FAQ

Can you provide the ChartMill fundamental rating for ImmunoGen Inc?

ChartMill assigns a fundamental rating of 3 / 10 to IMGN.


What is the valuation status for IMGN stock?

ChartMill assigns a valuation rating of 3 / 10 to ImmunoGen Inc (IMGN). This can be considered as Overvalued.


What is the profitability of IMGN stock?

ImmunoGen Inc (IMGN) has a profitability rating of 2 / 10.


Can you provide the financial health for IMGN stock?

The financial health rating of ImmunoGen Inc (IMGN) is 4 / 10.


Can you provide the expected EPS growth for IMGN stock?

The Earnings per Share (EPS) of ImmunoGen Inc (IMGN) is expected to grow by 108.78% in the next year.